Overview

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

Status:
Completed

Trial end date:
2017-08-02

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled, multicenter, pre-operative Phase II study designed to estimate the efficacy of ipatasertib combined with paclitaxel chemotherapy versus placebo combined with paclitaxel chemotherapy in women with Stage Ia - IIIa triple-negative breast adenocarcinoma. The anticipated time on study treatment is 12 weeks.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Collaborator:

SOLTI Breast Cancer Research Group

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel